Loading...
Compass Ratings
The Alexandria Compass
1,002+ stocks rated across NYSE & NASDAQ. Every stock scored 1–100 blending quantitative financials with qualitative moat, catalyst, and theme analysis — updated daily.
Theme Navigation
Browse Alexandria's ratings universe through its major market themes.
Coverage Universe
1,002 rated stocks organized through the Compass framework.
Updated daily
| Logo | Tier | Category | ||||||
|---|---|---|---|---|---|---|---|---|
 | LLY | Eli Lilly and Company | 92 | True North | Biotech & Genomics | $1.0T | +32.0% | 39.3x |
 | DXCM | DexCom Inc. | 90 | True North | Biotech & Genomics | $32B | +20.0% | 33.5x |
 | RXRX | Recursion Pharmaceuticals | 90 | True North | Biotech & Genomics | $2B | +55.0% | - |
T | TGTX | TG Therapeutics, Inc. | 90 | True North | Biotech & Genomics | $8B | +70.3% | 19.4x |
D | DNTH | Dianthus Therapeutics, Inc. | 90 | True North | Biotech & Genomics | $5B | +294.3% | - |
H | HRMY | Harmony Biosciences Holdings, Inc. | 88 | True North | Biotech & Genomics | $2B | +30.3% | 12.8x |
 | ALNY | Alnylam Pharmaceuticals | 88 | True North | Biotech & Genomics | $30B | +40.0% | 37.9x |
 | REGN | Regeneron Pharmaceuticals | 87 | True North | Biotech & Genomics | $76B | +7.0% | 18.3x |
 | CRSP | CRISPR Therapeutics | 86 | True North | Biotech & Genomics | $5B | +68.6% | - |
C | CAI | Caris Life Sciences, Inc. | 86 | True North | Biotech & Genomics | $8B | +45.4% | 16.3x |
K | KNSA | Kiniksa Pharmaceuticals International, plc | 85 | True North | Biotech & Genomics | $6B | +55.5% | 79.5x |
 | VRTX | Vertex Pharmaceuticals | 85 | True North | Biotech & Genomics | $128B | +12.0% | 29.3x |
 | BEAM | Beam Therapeutics | 85 | True North | Biotech & Genomics | $3B | 0.0% | - |
C | CLOV | Clover Health Investments, Corp. | 84 | True North | Biotech & Genomics | $2B | +62.0% | - |
L | LEGN | Legend Biotech Corporation | 83 | True North | Biotech & Genomics | $4B | +51.9% | - |
S | SEPN | Septerna, Inc. | 82 | True North | Biotech & Genomics | $2B | +12011.0% | - |
U | URGN | UroGen Pharma Ltd. | 82 | True North | Biotech & Genomics | $2B | +151.6% | - |
C | CRON | Cronos Group Inc. | 82 | True North | Biotech & Genomics | $1B | +40.1% | 16.9x |
A | ABUS | Arbutus Biopharma Corporation | 82 | True North | Biotech & Genomics | $641M | +10054.5% | 5.3x |
P | PRLD | Prelude Therapeutics Incorporated | 82 | True North | Biotech & Genomics | $310M | +116.7% | - |
C | CRMD | CorMedix Inc. | 82 | True North | Biotech & Genomics | $571M | +226.1% | 3.6x |
C | CARL | Carlsmed, Inc. | 82 | True North | Biotech & Genomics | $384M | +58.2% | - |
S | SRTA | Strata Critical Medical, Inc. | 82 | True North | Biotech & Genomics | $395M | +87.4% | - |
O | OABI | OmniAb, Inc. | 82 | True North | Biotech & Genomics | $678M | +247.3% | - |
X | XERS | Xeris Biopharma Holdings, Inc. | 82 | True North | Biotech & Genomics | $2B | +38.3% | - |
P | PRTC | PureTech Health plc | 82 | True North | Biotech & Genomics | $424M | -38.2% | 9.2x |
A | AVR | Anteris Technologies Global Corp. | 82 | True North | Biotech & Genomics | $646M | +63.3% | - |
A | AGIO | Agios Pharmaceuticals, Inc. | 82 | True North | Biotech & Genomics | $2B | +259.3% | - |
Z | ZVRA | Zevra Therapeutics, Inc. | 82 | True North | Biotech & Genomics | $653M | +77.5% | 12.0x |
G | GLPG | Lakefront Biotherapeutics NV | 82 | True North | Biotech & Genomics | $2B | -91.4% | 3.2x |
V | VSTM | Verastem, Inc. | 82 | True North | Biotech & Genomics | $734M | +1775.4% | - |
L | LXRX | Lexicon Pharmaceuticals, Inc. | 82 | True North | Biotech & Genomics | $783M | +1572.1% | - |
A | ARVN | Arvinas, Inc. | 82 | True North | Biotech & Genomics | $485M | +1014.7% | 28.9x |
A | AKTS | Aktis Oncology, Inc. | 82 | True North | Biotech & Genomics | $987M | +123.0% | - |
K | KMTS | Kestra Medical Technologies, Ltd. | 82 | True North | Biotech & Genomics | $2B | +62.7% | - |
F | FDMT | 4D Molecular Therapeutics, Inc. | 82 | True North | Biotech & Genomics | $702M | +21664.3% | - |
I | IRWD | Ironwood Pharmaceuticals, Inc. | 82 | True North | Biotech & Genomics | $639M | +32.6% | 5.0x |
A | AGEN | Agenus Inc. | 82 | True North | Biotech & Genomics | $341M | +34.4% | 3.0x |
S | SNDA | Sonida Senior Living, Inc. | 82 | True North | Biotech & Genomics | $2B | +137.1% | - |
T | TARS | Tarsus Pharmaceuticals, Inc. | 81 | True North | Biotech & Genomics | $3B | +106.9% | - |
P | PRE | Prenetics Global Limited | 81 | True North | Biotech & Genomics | $429M | +210.7% | - |
 | SYK | Stryker Corporation | 81 | True North | Biotech & Genomics | $106B | +10.0% | 28.7x |
S | SENS | Senseonics Holdings, Inc. | 79 | True North | Biotech & Genomics | $477M | +87.2% | - |
B | BLLN | BillionToOne, Inc. | 79 | True North | Biotech & Genomics | $5B | +83.8% | 151.4x |
N | NUVB | Nuvation Bio Inc. | 79 | True North | Biotech & Genomics | $2B | +555.6% | - |
A | ASTH | Astrana Health, Inc. | 79 | True North | Biotech & Genomics | $2B | +48.5% | 43.2x |
S | SLN | Silence Therapeutics plc | 78 | True North | Biotech & Genomics | $592M | +197.2% | - |
R | RIGL | Rigel Pharmaceuticals, Inc. | 78 | True North | Biotech & Genomics | $910M | +10.3% | 2.9x |
P | PNTG | The Pennant Group, Inc. | 78 | True North | Biotech & Genomics | $1B | +35.8% | 44.4x |
E | EBS | Emergent BioSolutions Inc. | 78 | True North | Biotech & Genomics | $349M | +66.3% | - |